Diagnosing lung cancer using etoposide microparticles labeled with 99mTc

20Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The diagnosis of lung cancer mostly occurs when the cancer is already in an advanced stage. In this situation, there are few options for the treatment and most of them have few chances of success. In this study, we developed and tested etoposide microparticles as a diagnostic agent for imaging lung cancer at early stages of development. We tested etoposide microparticles labeled with technetium 99m in inducted mice. The results demonstrated that over 10% of the total dose used was uptake by the tumor site. Also, the results showed that the microparticles had a good renal clearance and low uptake by liver and spleen. The data suggest that these micro-radiopharmaceuticals may be used for lung cancer imaging exam, especially single-photo emission computed tomography (SPECT). (Figure presented.).

Cite

CITATION STYLE

APA

Salvi, R., Cerqueira-Coutinho, C., Ricci-Junior, E., dos Santos, S. N., Pinto, S. R., Bernardes, E. S., … Santos-Oliveira, R. (2018). Diagnosing lung cancer using etoposide microparticles labeled with 99mTc. Artificial Cells, Nanomedicine and Biotechnology, 46(2), 341–345. https://doi.org/10.1080/21691401.2017.1307848

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free